Tildrakizumab in Complex Psoriatic Patients: An Experience in Emilia-Romagna (Italy).

BACKGROUND

IL-23 inhibitors are the latest class of biologic drugs approved for moderate-to-severe psoriasis.

OBJECTIVES

to investigate real-life safety and efficacy of tildrakizumab.

METHODS

demographic data, medical history, psoriasis disease history, PASI, DLQI, BSA, NAPSI were recorded at weeks 0, 12, 24, 36.

RESULTS

PASI, BSA, DLQI and NAPSI all decreased rapidly during the 36 week follow-up period. PASI score reduced from 12.28 to 4.65 by week 12, followed by a further decrease to 1.18 at week 36 Multiple logistic regression showed that smoking, BMI ≥30, ≥3 comorbidities, previous systemic traditional or biologic drugs, psoriatic arthritis nor difficult-to-treat areas influenced the reduction of PASI and NAPSI scores during treatment with tildrakizumab (P > .05).

CONCLUSIONS

we assessed a good performance of tildrakizumab in patients with multiple comorbidities, multi-failure, elderly patients, and in subjects with psoriatic arthritis.